Effects of high frequency rTMS on nociceptive pain in Parkinson's disease - Towards a personalized mechanism-based therapeutic approach.

Competing Interests: Declaration of competing interest SA declares having received compensation from Sanofi Aventis, France; Novartis, France; Exoneural Network AB, Sweden and Ottobock, France. MC received compensation from Janssen Global Services LLC, Exoneural Network AB, Sweden, and Ottobock, France. VM consulted for Abbvie and BIAL, and received research grants from Parkinson Switzerland, Hurka Foundation, Zambon, and Mundipharma; as well as honoraria from Zambon, Abbvie, Everpharma, and BIAL.